Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.

Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD.

Blood Adv. 2020 Apr 14;4(7):1311-1320. doi: 10.1182/bloodadvances.2019001267.

PMID:
32251497
2.

Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.

Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R.

Mod Pathol. 2020 Apr 1. doi: 10.1038/s41379-020-0531-2. [Epub ahead of print]

PMID:
32238878
3.

Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial.

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens D, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald AB, Chyla B, Gopalakrishnan S, Jiang Q, Mendes WL, Hayslip J, Panayiotidis P.

Blood. 2020 Mar 27. pii: blood.2020004856. doi: 10.1182/blood.2020004856. [Epub ahead of print]

PMID:
32219442
4.

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.

Sasaki K, Kantarjian H, Wierda W, Ravandi F, Daver N, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Z, Konopleva M, Ohanian M, Garcia-Manero G, Kadia T, Alvarado Y, Yilmaz M, Pierce S, Garris R, Cortes J, O'Brien S, Ingram A, Jabbour E.

Am J Hematol. 2020 Mar 14. doi: 10.1002/ajh.25784. [Epub ahead of print]

PMID:
32170867
5.

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.

Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM.

Lancet Haematol. 2020 Apr;7(4):e309-e319. doi: 10.1016/S2352-3026(19)30284-4. Epub 2020 Mar 5.

PMID:
32145771
6.

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.

Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N.

Cancer. 2020 Mar 3. doi: 10.1002/cncr.32796. [Epub ahead of print]

PMID:
32125707
7.

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.

Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM.

Am J Hematol. 2020 Feb 28. doi: 10.1002/ajh.25769. [Epub ahead of print]

PMID:
32112433
8.

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.

Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F.

Leukemia. 2020 Feb 25. doi: 10.1038/s41375-020-0778-0. [Epub ahead of print] No abstract available.

PMID:
32099037
9.

Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors.

Saenz D, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury J, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN.

Blood. 2020 Feb 14. pii: blood.2019002922. doi: 10.1182/blood.2019002922. [Epub ahead of print]

PMID:
32068780
10.

Venetoclax in acute myeloid leukemia - current and future directions.

Lachowiez C, DiNardo CD, Konopleva M.

Leuk Lymphoma. 2020 Feb 7:1-10. doi: 10.1080/10428194.2020.1719098. [Epub ahead of print]

PMID:
32031033
11.

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver N.

Cancer Discov. 2020 Apr;10(4):506-525. doi: 10.1158/2159-8290.CD-19-1011. Epub 2020 Feb 3. Review.

PMID:
32014868
12.

Effectiveness of strategies to screen for blood donors with RH variants in a mixed population.

de Almeida FAA, Dezan MR, Oliveira VB, Alencar CS, Luz F, Krieger JE, Pereira AC, Sabino EC, Rocha V, Mendrone-Júnior A, Dinardo CL.

Transfus Apher Sci. 2020 Jan 15:102720. doi: 10.1016/j.transci.2020.102720. [Epub ahead of print]

PMID:
31980333
13.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH.

Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.

PMID:
31932844
14.

Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.

Myers KC, Furutani E, Weller E, Siegele B, Galvin A, Arsenault V, Alter BP, Boulad F, Bueso-Ramos C, Burroughs L, Castillo P, Connelly J, Davies SM, DiNardo CD, Hanif I, Ho RH, Karras N, Manalang M, McReynolds LJ, Nakano TA, Nalepa G, Norkin M, Oberley MJ, Orgel E, Pastore YD, Rosenthal J, Walkovich K, Larson J, Malsch M, Elghetany MT, Fleming MD, Shimamura A.

Lancet Haematol. 2020 Mar;7(3):e238-e246. doi: 10.1016/S2352-3026(19)30206-6. Epub 2019 Dec 23.

PMID:
31879230
15.

Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response.

Stein EM, DiNardo CD, Pollyea DA, Schuh AC.

Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e66-e75. doi: 10.1016/j.clml.2019.11.017. Epub 2019 Nov 26. Review.

16.

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM.

Blood. 2020 Feb 13;135(7):463-471. doi: 10.1182/blood.2019002140.

17.

Single-agent and combination biologics in acute myeloid leukemia.

Richard-Carpentier G, DiNardo CD.

Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):548-556. doi: 10.1182/hematology.2019000059.

PMID:
31808888
18.

Which novel agents hold the greatest promise in AML?

DiNardo CD.

Best Pract Res Clin Haematol. 2019 Dec;32(4):101106. doi: 10.1016/j.beha.2019.101106. Epub 2019 Oct 18. Review.

PMID:
31779980
19.

How I treat acute myeloid leukemia in the era of new drugs.

DiNardo CD, Wei AH.

Blood. 2020 Jan 9;135(2):85-96. doi: 10.1182/blood.2019001239.

PMID:
31765470
20.

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy.

Richard-Carpentier G, DiNardo CD.

Ther Adv Hematol. 2019 Oct 23;10:2040620719882822. doi: 10.1177/2040620719882822. eCollection 2019. Review.

21.

Clinical and Genetic Predictors of Priapism in Sickle Cell Disease: Results from the Recipient Epidemiology and Donor Evaluation Study III Brazil Cohort Study.

Cintho Ozahata M, Page GP, Guo Y, Ferreira JE, Dinardo CL, Carneiro-Proietti ABF, Loureiro P, Mota RA, Rodrigues DOW, Belisario AR, Maximo C, Flor-Park MV, Custer B, Kelly S, Sabino EC; International Component of the NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS-III).

J Sex Med. 2019 Dec;16(12):1988-1999. doi: 10.1016/j.jsxm.2019.09.012. Epub 2019 Oct 24.

PMID:
31668730
22.

ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.

Luo X, Feurstein S, Mohan S, Porter CC, Jackson SA, Keel S, Chicka M, Brown AL, Kesserwan C, Agarwal A, Luo M, Li Z, Ross JE, Baliakas P, Pineda-Alvarez D, DiNardo CD, Bertuch AA, Mehta N, Vulliamy T, Wang Y, Nichols KE, Malcovati L, Walsh MF, Rawlings LH, McWeeney SK, Soulier J, Raimbault A, Routbort MJ, Zhang L, Ryan G, Speck NA, Plon SE, Wu D, Godley LA.

Blood Adv. 2019 Oct 22;3(20):2962-2979. doi: 10.1182/bloodadvances.2019000644.

23.

Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know.

Shah M, Rajha E, DiNardo C, Muckey E, Wierda WG, Yeung SJ.

Ann Emerg Med. 2020 Feb;75(2):264-286. doi: 10.1016/j.annemergmed.2019.07.015. Epub 2019 Sep 24. Review.

PMID:
31561995
24.

Diversity of RH and transfusion support in Brazilian sickle cell disease patients with unexplained Rh antibodies.

Dinardo CL, Kelly S, Dezan MR, Ribeiro IH, Castilho SL, Schimidt LC, Valgueiro MDC, Preiss LR, Custer B, Sabino EC, Westhoff CM; NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS)-III.

Transfusion. 2019 Oct;59(10):3228-3235. doi: 10.1111/trf.15479. Epub 2019 Aug 13.

PMID:
31408202
25.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM.

Lancet Haematol. 2019 Sep;6(9):e480-e488. doi: 10.1016/S2352-3026(19)30114-0. Epub 2019 Aug 7.

PMID:
31400961
26.

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.

Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD.

Am J Hematol. 2020 Feb;95(2):227-229. doi: 10.1002/ajh.25610. Epub 2019 Aug 29. No abstract available.

PMID:
31400013
27.

Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.

DiNardo C, Lachowiez C.

Curr Hematol Malig Rep. 2019 Oct;14(5):386-394. doi: 10.1007/s11899-019-00535-7. Review.

PMID:
31350639
28.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F.

Cancer. 2019 Nov 1;125(21):3755-3766. doi: 10.1002/cncr.32387. Epub 2019 Jul 16.

PMID:
31310323
29.

Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies.

Clifford M, Bannon S, Bednar EM, Czerwinski J, Davis J, Dunnington L, Shahrukh Hashmi S, DiNardo CD.

Leuk Lymphoma. 2019 Dec;60(12):3020-3027. doi: 10.1080/10428194.2019.1630618. Epub 2019 Jul 5.

PMID:
31274040
30.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Sep;94(9):984-991. doi: 10.1002/ajh.25553. Epub 2019 Jun 24.

PMID:
31237017
31.

Hereditary myeloid malignancies.

Rafei H, DiNardo CD.

Best Pract Res Clin Haematol. 2019 Jun;32(2):163-176. doi: 10.1016/j.beha.2019.05.001. Epub 2019 May 3. Review.

PMID:
31203998
32.

Venetoclax-based therapies for acute myeloid leukemia.

Guerra VA, DiNardo C, Konopleva M.

Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24. Review.

PMID:
31203996
33.

Prevalence and laboratorial determinants of the clinical relevance of antibodies of undetermined specificity.

de Albuquerque da Veiga Conrado MC, Cardoso RA, Dezan MR, Oliveira VB, Neto ADC, Ziza KC, Krieger JE, Pereira AC, Sabino EC, Rocha V, Mendrone-Júnior A, Dinardo CL.

Vox Sang. 2019 Aug;114(6):616-621. doi: 10.1111/vox.12797. Epub 2019 Jun 10.

PMID:
31183870
34.

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.

Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M.

Cancer. 2019 Sep 15;125(18):3219-3224. doi: 10.1002/cncr.32196. Epub 2019 May 31.

PMID:
31150121
35.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W.

N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

PMID:
31141631
36.

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.

Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M.

Haematologica. 2020 Mar;105(3):697-707. doi: 10.3324/haematol.2018.205534. Epub 2019 May 23.

37.

Severe therapy-related toxicities after treatment for Hodgkin lymphoma due to a pathogenic TERT variant and shortened telomeres.

Agrusa JE, Bertuch AA, DiNardo CD, Plon SE, Eckstein OS.

Pediatr Blood Cancer. 2019 Aug;66(8):e27779. doi: 10.1002/pbc.27779. Epub 2019 May 2.

PMID:
31050187
38.

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.

Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN.

Blood. 2019 Jul 4;134(1):59-73. doi: 10.1182/blood.2018893982. Epub 2019 Apr 25.

PMID:
31023702
39.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.

Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F.

Am J Hematol. 2019 Jul;94(7):E188-E190. doi: 10.1002/ajh.25490. Epub 2019 Apr 29. No abstract available.

PMID:
30977182
40.

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM.

Leukemia. 2019 Nov;33(11):2575-2584. doi: 10.1038/s41375-019-0472-2. Epub 2019 Apr 9.

PMID:
30967620
41.

DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.

Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP.

Am J Hematol. 2019 Jul;94(7):757-766. doi: 10.1002/ajh.25486. Epub 2019 May 7.

PMID:
30963592
42.

Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia.

Alfayez M, Ivan D, Pemmaraju N, Daver N, DiNardo CD.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00198. Epub 2019 Feb 6. No abstract available.

43.

SMIM1 intron 2 gene variations leading to variability in Vel antigen expression among Brazilian blood donors.

Dezan MR, Costa-Neto A, Gomes CN, Ribeiro IH, Oliveira VB, Conrado MCAV, Oliveira TGM, Carvalho MLP, Aranha AF, Bosi SRA, Salles NA, Krieger JE, Pereira AC, Sabino EC, Rocha V, Mendrone-Junior A, Dinardo CL, Levi JE.

Blood Cells Mol Dis. 2019 Jul;77:23-28. doi: 10.1016/j.bcmd.2019.03.006. Epub 2019 Mar 25.

PMID:
30939337
44.

A Toll-like receptor 2 genetic variant modulates occurrence of bacterial infections in patients with sickle cell disease.

Tozatto-Maio K, Girot R, Ly ID, Rocha V, Silva Pinto AC, Diagne I, Benzerara Y, Dinardo CL, Kashima S, Leston-Araujo I, Kenzey C, Fonseca GHH, Rodrigues ES, Volt F, Jarduli LR, Ruggeri A, Mariaselvam CM, Gualandro SFM, Elayoubi H, Cunha R, Cappelli B, Malmegrim KCR, Simões BP, Gluckman E, Tamouza R.

Br J Haematol. 2019 Jun;185(5):918-924. doi: 10.1111/bjh.15875. Epub 2019 Mar 25.

PMID:
30908604
45.

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.

Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G.

Blood Adv. 2019 Mar 26;3(6):922-933. doi: 10.1182/bloodadvances.2018026989.

46.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.

Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S.

Cancer. 2019 Jun 1;125(11):1855-1866. doi: 10.1002/cncr.31986. Epub 2019 Feb 27.

PMID:
30811597
47.

A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing.

Chinoca Ziza KN, Paiva TA, Mota SR, Dezan MR, Schmidt LC, Brunetta DM, Ricci G, Basques FV, Barroso-Duarte F, Rocha V, Mendrone-Junior A, Dinardo CL.

Transfusion. 2019 May;59(5):1827-1835. doi: 10.1111/trf.15202. Epub 2019 Feb 18.

PMID:
30779172
48.

A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure.

Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD.

Leuk Lymphoma. 2019 Sep;60(9):2207-2213. doi: 10.1080/10428194.2019.1576873. Epub 2019 Feb 18.

PMID:
30773968
49.

Hematologic malignancies and Li-Fraumeni syndrome.

Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD.

Cold Spring Harb Mol Case Stud. 2019 Feb 1;5(1). pii: a003210. doi: 10.1101/mcs.a003210. Print 2019 Feb. Review.

50.

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.

Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK.

Cancer. 2019 May 15;125(10):1665-1673. doi: 10.1002/cncr.31923. Epub 2019 Jan 22.

PMID:
30668890

Supplemental Content

Loading ...
Support Center